Biolase (BIOL) Misses Q4 EPS by 3c, Offers Guidance

Biolase (NASDAQ: BIOL) reported Q4 EPS of ($0.07), $0.03 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $8.34 million.

GUIDANCE:

Biolase sees Q1 2021 revenue of $7.5-8 million.

• For the first quarter ending March 31, 2021, the Company expects total revenue of $7.5 million to $8.0 million, which would represent growth between 60% and 70% year over year.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Madison Square Garden Sports Corp. (MSGS) Tops Q4 EPS by 62c
• Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance